Statements (61)
| Predicate | Object |
|---|---|
| gptkbp:instance_of |
gptkb:drug
|
| gptkbp:bfsLayer |
3
|
| gptkbp:bfsParent |
gptkb:Schering_AG
|
| gptkbp:activities |
H1 receptor antagonist
|
| gptkbp:approves |
gptkb:1993
gptkb:FDA |
| gptkbp:average_temperature |
room temperature
|
| gptkbp:clinical_trial |
Phase IV
Phase III treatment of chronic urticaria treatment of allergic conjunctivitis treatment of skin allergies treatment of allergic rhinitis treatment of hay fever |
| gptkbp:color |
gptkb:white
|
| gptkbp:contraindication |
lactation
pregnancy category B hypersensitivity to loratadine |
| gptkbp:dosage_form |
10 mg once daily
10 mg tablet 10 mg orally disintegrating tablet 5 mg chewable tablet 5 mg/5 m L syrup |
| gptkbp:excretion |
urine
feces |
| gptkbp:flavor |
gptkb:fair
|
| gptkbp:form |
gptkb:product
gptkb:tablet |
| https://www.w3.org/2000/01/rdf-schema#label |
Clarityn
|
| gptkbp:ingredients |
gptkb:loratadine
|
| gptkbp:interacts_with |
gptkb:beer
CY P2 D6 inhibitors CY P3 A4 inhibitors |
| gptkbp:invention |
gptkb:2011
|
| gptkbp:is_available_in |
liquid form
orally disintegrating tablet chewable form |
| gptkbp:is_available_on |
gptkb:drug
|
| gptkbp:is_used_for |
allergy relief
|
| gptkbp:lifespan |
8 hours
|
| gptkbp:manufacturer |
gptkb:Bristol-Myers_Squibb
|
| gptkbp:marketed_as |
gptkb:Clarinex
gptkb:Claritin gptkb:Alavert |
| gptkbp:metabolism |
liver
|
| gptkbp:packaging |
gptkb:beer
blister pack |
| gptkbp:previous_name |
gptkb:loratadine
|
| gptkbp:related_to |
hay fever
perennial allergic rhinitis seasonal allergic rhinitis |
| gptkbp:side_effect |
fatigue
headache nausea rash drowsiness dry mouth anaphylaxis thrombocytopenia palpitations elevated liver enzymes |